STOCK TITAN
  1. Home
  2. News
  3. VEEV
  4. New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
A new Veeva MedTech study reveals that 88% of medtech companies plan to modernize their postmarket quality management within three years. The 2025 benchmark report, surveying over 100 quality leaders, shows that 68% still rely on manual or legacy systems, potentially causing delays in addressing product issues. Key findings indicate that 38% of companies prioritize proactive and risk-based quality management, while 26% focus on scaling processes for growth. 75% believe advanced technology can drive automation for efficiency, and 62% see value in connecting quality management processes. However, emerging technologies like AI and automation show limited adoption at less than 3%. The study also highlights a significant training gap, with only 19% of respondents confident in their current training programs for postmarket quality teams.
Un nuovo studio di Veeva MedTech rivela che l'88% delle aziende medtech prevede di modernizzare la gestione della qualità postmercato entro tre anni. Il rapporto di riferimento 2025, basato su un sondaggio con oltre 100 responsabili della qualità, mostra che il 68% si affida ancora a sistemi manuali o legacy, con possibili ritardi nella risoluzione dei problemi dei prodotti. I risultati principali indicano che il 38% delle aziende dà priorità a una gestione della qualità proattiva e basata sul rischio, mentre il 26% si concentra sull'espansione dei processi per la crescita. Il 75% ritiene che le tecnologie avanzate possano favorire l'automazione per aumentare l'efficienza, e il 62% riconosce il valore di connettere i processi di gestione della qualità. Tuttavia, l'adozione di tecnologie emergenti come l'IA e l'automazione è ancora limitata, inferiore al 3%. Lo studio evidenzia anche un significativo divario formativo, con solo il 19% degli intervistati sicuro dei programmi di formazione attuali per i team di qualità postmercato.
Un nuevo estudio de Veeva MedTech revela que el 88% de las empresas medtech planean modernizar la gestión de calidad postmercado en un plazo de tres años. El informe de referencia 2025, que encuestó a más de 100 líderes de calidad, muestra que el 68% todavía depende de sistemas manuales o heredados, lo que puede ocasionar retrasos en la resolución de problemas de productos. Los hallazgos clave indican que el 38% de las empresas priorizan una gestión de calidad proactiva y basada en riesgos, mientras que el 26% se enfoca en escalar procesos para el crecimiento. El 75% cree que la tecnología avanzada puede impulsar la automatización para mejorar la eficiencia, y el 62% valora la conexión de los procesos de gestión de calidad. Sin embargo, la adopción de tecnologías emergentes como la IA y la automatización es limitada, con menos del 3%. El estudio también destaca una brecha significativa en la formación, ya que solo el 19% de los encuestados confía en sus programas de capacitación actuales para los equipos de calidad postmercado.
Veeva MedTech의 새로운 연구에 따르면, 의료기기 회사의 88%가 향후 3년 내에 사후 시장 품질 관리를 현대화할 계획인 것으로 나타났습니다. 2025년 벤치마크 보고서는 100명 이상의 품질 리더를 대상으로 조사한 결과, 68%가 여전히 수동 또는 기존 시스템에 의존하고 있어 제품 문제 해결에 지연이 발생할 수 있음을 보여줍니다. 주요 결과로는 38%의 기업이 선제적이고 위험 기반의 품질 관리를 우선시하며, 26%는 성장에 맞춘 프로세스 확장에 집중하고 있습니다. 75%는 첨단 기술이 효율성을 위한 자동화를 촉진할 수 있다고 믿으며, 62%는 품질 관리 프로세스 연결의 가치를 인식하고 있습니다. 그러나 AI 및 자동화와 같은 신기술의 도입률은 3% 미만으로 제한적입니다. 또한 연구는 사후 시장 품질 팀을 위한 현재 교육 프로그램에 대해 자신감을 가진 응답자가 19%에 불과한 교육 격차도 강조합니다.
Une nouvelle étude de Veeva MedTech révèle que 88 % des entreprises medtech prévoient de moderniser leur gestion de la qualité post-commercialisation dans les trois ans à venir. Le rapport de référence 2025, basé sur une enquête auprès de plus de 100 responsables qualité, montre que 68 % dépendent encore de systèmes manuels ou hérités, ce qui peut entraîner des retards dans la résolution des problèmes produits. Les principales conclusions indiquent que 38 % des entreprises privilégient une gestion de la qualité proactive et basée sur les risques, tandis que 26 % se concentrent sur la montée en puissance des processus pour soutenir la croissance. 75 % estiment que les technologies avancées peuvent favoriser l'automatisation pour améliorer l'efficacité, et 62 % voient un intérêt à connecter les processus de gestion de la qualité. Cependant, l'adoption des technologies émergentes telles que l'IA et l'automatisation reste limitée, à moins de 3 %. L'étude souligne également un important déficit de formation, avec seulement 19 % des répondants confiants dans leurs programmes actuels de formation des équipes qualité post-commercialisation.
Eine neue Studie von Veeva MedTech zeigt, dass 88 % der Medtech-Unternehmen planen, ihr Qualitätsmanagement nach dem Inverkehrbringen innerhalb von drei Jahren zu modernisieren. Der Benchmark-Bericht 2025, der über 100 Qualitätsleiter befragte, zeigt, dass 68 % noch auf manuelle oder veraltete Systeme angewiesen sind, was zu Verzögerungen bei der Behebung von Produktproblemen führen kann. Wichtige Erkenntnisse zeigen, dass 38 % der Unternehmen proaktives und risikobasiertes Qualitätsmanagement priorisieren, während 26 % den Fokus auf die Skalierung von Prozessen für Wachstum legen. 75 % glauben, dass fortschrittliche Technologien Automatisierung zur Effizienzsteigerung vorantreiben können, und 62 % sehen den Wert in der Vernetzung von Qualitätsmanagementprozessen. Die Einführung neuer Technologien wie KI und Automatisierung ist jedoch mit weniger als 3 % noch gering. Die Studie hebt zudem eine erhebliche Ausbildungslücke hervor, da nur 19 % der Befragten Vertrauen in ihre aktuellen Schulungsprogramme für Postmarket-Qualitätsteams haben.
Positive
  • 88% of medtech companies planning to modernize quality management shows strong industry commitment to improvement
  • 75% of companies recognize technology's potential for automation and efficiency
  • Survey reveals clear strategic priorities with 38% focusing on proactive quality management
  • 62% of companies understand the value of connected quality management processes
Negative
  • 68% still rely on manual processes or legacy systems, risking delays and compliance issues
  • Less than 3% have successfully implemented AI and automation technologies
  • Only 19% have sufficient training programs for postmarket quality teams
  • Current manual processes causing delays in addressing product issues and complaint handling backlogs

Industry focused on automation, connectivity, and reporting for proactive quality management

PLEASANTON, Calif., June 9, 2025 /PRNewswire/ -- The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality management within the next three years to improve compliance and drive innovation. This signals a shift toward modernization to reduce risk and foster a stronger culture of quality across the product lifecycle.

While the move to more scalable solutions is planned or underway for most, 68% of medtechs currently rely on manual processes, a mix of paper-based and electronic systems, or legacy on-premise solutions. This can cause delays in addressing product issues and lead to backlogs in complaint handling. Companies with slow response times to patient safety concerns incur significant risks in compliance, consumer trust, and brand reputation.

The research highlights opportunities for medtechs to streamline quality operations for proactive management and execution, including: 

An emphasis on proactive action. The primary drivers to advance quality are proactive and risk-based quality management (38%) and scaling processes to support growth (26%) to adapt to market changes. 

Technology viewed as an enabler. With more than half of medtechs working on manual processes, most respondents say advanced technology can drive automation for faster timelines and efficiency (75%), connections with other quality management system processes (62%), and advanced reporting for data-driven decision-making (61%). 

Generative AI, intelligent automation, and robotic process automation scarcely adopted. Less than 3% of companies have reliably applied these emerging technologies across their organizations. Despite limited adoption, there is strong optimism about the potential of these technologies, with improving timeliness and efficiency ranked as the top opportunities. 

Gaps in employee training exist. Only 19% of respondents say their training programs are sufficient to support postmarket quality teams for future success. This presents an opportunity to introduce an interactive learning approach that ensures employees receive real-time updates and guidance on job responsibilities.

"While initiatives are underway to simplify and connect medtech quality operations, the research reveals that many of the organizations surveyed are limited by legacy systems and manual processes," said Vishaka Rajaram, senior director of quality strategy at Veeva MedTech. "By aligning strategic goals with modern technology solutions, medtechs can move from reactive issue management to proactive risk prevention for greater speed and compliance."

The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed more than 100 quality medtech leaders, examining the medical device and diagnostic industry's progress, challenges, and opportunities in quality management. To learn more, read the benchmark report here. 

About Veeva Systems
Veeva (NYSE: VEEV) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-finds-88-of-medtechs-prioritizing-postmarket-quality-modernization-within-next-3-years-302475047.html

SOURCE Veeva Systems

FAQ

What percentage of medtech companies are prioritizing postmarket quality modernization according to Veeva's 2025 study?

According to Veeva's 2025 study, 88% of medtech companies are prioritizing postmarket quality modernization within the next three years.

What are the main challenges in medtech quality management identified in the Veeva (VEEV) report?

The main challenges include 68% still using manual or legacy systems, less than 3% adoption of AI and automation, and only 19% having sufficient training programs.

How many medtech companies currently use manual or legacy systems for quality management?

68% of medtech companies currently rely on manual processes, paper-based systems, or legacy on-premise solutions.

What percentage of medtech companies focus on proactive and risk-based quality management?

38% of medtech companies focus on proactive and risk-based quality management as their primary driver for advancement.

How many quality medtech leaders participated in Veeva's 2025 benchmark report?

The 2025 Veeva MedTech Postmarket Quality Benchmark Report surveyed more than 100 quality medtech leaders.
Stock VEEV logo
Veeva Sys Inc

NYSE:VEEV

VEEV Rankings

#300 Ranked by Market Cap
N/A Ranked by Dividends

VEEV Latest News

Jun 4, 2025
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
Jun 4, 2025
Astellas Chooses Veeva Vault CRM as Global Standard
May 30, 2025
Veeva to Present at Upcoming Investor Conferences
May 29, 2025
Veeva Pulse Report Finds Content-Driven Engagement Lags Despite Proven Boost to Treatment Adoption
May 28, 2025
Veeva Announces Fiscal 2026 First Quarter Results

VEEV Stock Data

45.60B
149.42M
8.92%
85.05%
2.46%
Health Information Services
Services-prepackaged Software
Link
United States
PLEASANTON

Related Articles

Continue reading with these related stories

View All Latest News